×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:GLMD

Galmed Pharmaceuticals Stock Forecast, Price & News

$0.62
-0.03 (-5.35%)
(As of 07/1/2022 08:44 PM ET)
Add
Compare
Today's Range
$0.59
$0.70
50-Day Range
$0.44
$1.66
52-Week Range
$0.42
$3.42
Volume
40,700 shs
Average Volume
109,060 shs
Market Capitalization
$15.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Galmed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
712.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Galmed Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.66) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.51 out of 5 stars

Medical Sector

982nd out of 1,412 stocks

Pharmaceutical Preparations Industry

482nd out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GLMD Stock News Headlines

Galmed Pharmaceuticals Shares Down 16%
Galmed Pharmaceuticals's Earnings Outlook
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
18
Year Founded
N/A

Company Calendar

Last Earnings
5/17/2022
Today
7/04/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+712.7%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
2 Analysts

Profitability

Net Income
$-32.47 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.22 per share

Miscellaneous

Free Float
N/A
Market Cap
$15.43 million
Optionable
Optionable
Beta
1.53














Galmed Pharmaceuticals Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Galmed Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View analyst ratings for Galmed Pharmaceuticals
or view top-rated stocks.

What is Galmed Pharmaceuticals' stock price forecast for 2022?

2 equities research analysts have issued 12 month price targets for Galmed Pharmaceuticals' stock. Their GLMD stock forecasts range from $5.00 to $5.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 712.7% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Galmed Pharmaceuticals' stock performed in 2022?

Galmed Pharmaceuticals' stock was trading at $1.82 on January 1st, 2022. Since then, GLMD stock has decreased by 66.2% and is now trading at $0.6152.
View the best growth stocks for 2022 here
.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galmed Pharmaceuticals
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.09.
View Galmed Pharmaceuticals' earnings history
.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, Pres, CEO & Chairman (Age 57, Pay $1.71M)
  • Mr. Guy Nehemya, COO & Data Protection Officer (Age 37, Pay $168.93k)
  • Mr. Yohai Stenzler CPA, Chief Accounting Officer (Age 39, Pay $173.11k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 55, Pay $263.01k)
  • Mr. Doron Cohen, Chief Financial Officer (Age 55)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 39)
  • Ms. Shani Ganon, HR Mang.
  • Dr. Tali Gorfine, Medical Consultant (Age 52)
  • Mr. Niv Alon, Head of PMO
  • Ms. Topaz Falkoviz Arbel, Corp. Sec.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.62.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $15.43 million. The biopharmaceutical company earns $-32.47 million in net income (profit) each year or ($1.180010) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 18 workers across the globe.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for Galmed Pharmaceuticals is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.